Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases Journal Article
| Authors: | Gallagher, D. J.; Zheng, J.; Capanu, M.; Haviland, D.; Paty, P.; DeMatteo, R. P.; D'Angelica, M.; Fong, Y.; Jarnagin, W. R.; Allen, P. J.; Kemeny, N. |
| Article Title: | Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases |
| Abstract: | Objective: We investigated the relation between response to neoadjuvant chemotherapy and overall survival (OS) in patients with colorectal liver metastases (CLM). Background: It has previously been reported that patients with synchronous CLM whose disease progresses while receiving neoadjuvant chemotherapy or who do not receive neoadjuvant chemotherapy experience worse survival than patients whose disease responds to neoadjuvant chemotherapy. Methods: By means of a prospectively maintained surgical database, between 1995 and 2003, we identified 111 patients with a synchronous CLM who received neoadjuvant chemotherapy before hepatic resection. The disease of all 111 patients was deemed resectable, and patients underwent hepatic resection with curative intent. Results: The median OS after liver resection was 62 months, with a median follow-up of 63 months. Median OS was similar between the three study groups classified by response to neoadjuvant chemotherapy (complete or partial response, 58 months; stable disease, 65 months; and disease progression, 61 months; P = .98). By univariate analysis, carcinoembryonic antigen level after liver resection of <5 ng/dL, size of metastatic lesion of ≤5 cm, lymph node-negative primary tumor, and disease-negative margins were associated with improved survival. Patients in the disease progression group had more positive margins and metastases >5 cm in size than patients in the complete or partial response group and the stable disease group. Patients whose tumor progressed but who received postoperative hepatic arterial infusion had a trend toward improved survival compared with those who did not receive hepatic arterial infusion (70% vs. 50% at 3 years, permutation log rank test P = .12). Conclusions: Response to neoadjuvant chemotherapy did not correlate with OS even after controlling for margins, stage of primary tumor, and postoperative carcinoembryonic antigen level. Postoperative salvage treatment may have helped the survival of some patients. © 2009 Society of Surgical Oncology. |
| Keywords: | adult; cancer survival; controlled study; treatment response; aged; aged, 80 and over; middle aged; survival analysis; retrospective studies; major clinical study; overall survival; clinical trial; fluorouracil; cancer growth; antineoplastic agents; liver neoplasms; adjuvant therapy; cancer adjuvant therapy; postoperative care; chemotherapy, adjuvant; neoadjuvant therapy; outcome assessment; follow up; prospective study; colorectal cancer; controlled clinical trial; tumor volume; carcinoembryonic antigen; prediction; patient identification; irinotecan; colorectal neoplasms; liver metastasis; disease progression; folinic acid; liver resection; oxaliplatin; databases as topic |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 16 |
| Issue: | 7 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2009-01-01 |
| Start Page: | 1844 |
| End Page: | 1851 |
| Language: | English |
| DOI: | 10.1245/s10434-009-0348-1 |
| PUBMED: | 19224284 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 7" - "Export Date: 30 November 2010" - "CODEN: ASONF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work